Dr. Hardin B. Jones Ph.D., spent 20 years of his life studying the effects of chemotherapy on patients with cancer.
What he found stunned the medical community. Jones found that people who refused or elected to not use chemotherapy lived longer lives than those who chose to opt-in to chemotherapy.
“My studies have proved conclusively that untreated cancer victims live up to four times longer than treated individuals. If one has cancer and opts to do nothing at all, he will live longer and feel better than if he undergoes radiation, chemotherapy or surgery, other than when used in immediate life-threatening situations.”—Prof Jones. (1956 Transactions of the N.Y. Academy of Medical Sciences, vol 6. There is a fifty page article by Hardin Jones of National Cancer Institute of Bethesda, Maryland.
The former professor of medical physics and physiology at the University of California at Berkeley was known for his critical and analytical thinking skills. He suggests that the primary focus of chemotherapy is that of profit for the pharmaceutical company who produces it. He asserts that it is a large-scale plan involving many health industry companies, not just pharmaceutical companies.
The chemotherapy method injects the patient with toxins which kill both good cells and bad cancer cells. Dr. Jones also surmised from his research that cancer patients who opt for chemotherapy mostly died in pain. The cancer industry has ignored all of his research and studies.
The American Cancer Society embraces the marketing component of urgency. They convince millions of people that “early diagnosis saves lives,” in order to broaden the chemotherapy application demographic.
Dr. Jones response to this is below:
In the matter of duration of malignant tumors before treatment, no studies have established the much talked about relationship between early detection and favorable survival after treatment…. Serious attempts to relate prompt treatment with chance of cure have been unsuccessful.
In some types of cancer, the opposite of the expected association of short duration of symptoms with a high chance of being “cured” has been observed. A long duration of symptoms before treatment in a few cancers of the breast and cervix is associated with longer than usual survival…. Neither the timing nor the extent of treatment of the true malignancies has appreciably altered the average course of the disease. The possibility exists that treatment makes the average situation worse.
Dr. Jones states that those who don’t opt for chemotherapy live on average, 12 years longer. Through his 20-year research program, he showed that conventional cancer therapy reduces life expectancy and accelerates the deterioration of the system.
Surgery Statistics from Hardin B. Jones, Ph.D.
One of the nation’s top statisticians in the field of cancer is Hardin B. Jones, Ph.D., former professor of medical physics and physiology at the University of California at Berkeley. After years of analyzing clinical records, this is the report he delivered at a convention of the American Cancer Society:
In regard to surgery, no relationship between intensity of surgical treatment and duration of survival has been found in verified malignancies. On the contrary, simple excision of cancers has produced essentially the same survival as radical excision and dissection of the lymphatic drainage. That data, of course, related to surgery of the breast. (Hardin B. Jones, Ph.D. “A Report on Cancer,” paper delivered to the ACS’s 11th Annual Science Writers Conference, New Orleans, Mar. 7, 1969.)
Turning his attention to surgery in general, Dr. Jones continued:
Although there is a dearth of untreated cases for statistical comparison with the treated, it is surprising that the death risks of the two groups remain so similar. In the comparisons it has been assumed that the treated and untreated cases are independent of each other. In fact, that assumption is incorrect. Initially, all cases are untreated. With the passage of time, some receive treatment, and the likelihood of treatment increases with the length of time since origin of the disease. Thus, those cases in which the neoplastic process progresses slowly [and thus automatically favors a long-term survival] are more likely to become “treated” cases. For the same reason, however, those individuals are likely to enjoy longer survival, whether treated or not. Life tables truly representative of untreated cancer patients must be adjusted for the fact that the inherently longer-lived cases are more likely to be transferred to the “treated” category than to remain in the “untreated until death.”
The apparent life expectancy of untreated cases of cancer after such adjustment in the table seems to be greater than that of the treated cases.